Home » Market News » DirectorsTalk Highlights » ImmuPharma’s Tim McCarthy updates on Lupuzor Phase III study
Immupharma Plc

ImmuPharma’s Tim McCarthy updates on Lupuzor Phase III study

Tim McCarthy, Chairman of ImmuPharma PLC (LON:IMM) tells Proactive Investors they’re on schedule to publish first results from their phase III trial of lupus drug Lupuzor early next year with all 200 patients now having had at least three months worth of treatment.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.